Table 6. Selected studies demonstrating inhibition of cell death by FB1.
N/D, not detected.
| Death inducer | Cell line/system | FB1 inhibits ceramide | FB1 inhibits death | Reference |
|---|---|---|---|---|
| Receptor-mediated | ||||
| TNF-α | MCF-7 breast carcinoma cells | + | + | [107] |
| L929 fibroblasts | + | + | [107] | |
| HL-60 promyelocytic leukaemia cells | + | + | [108] | |
| TNF-α/cycloheximide | Cerebral endothelial cells | + | + | [109] |
| B-cell receptor cross-linking | Ramos B-cells | + | + | [110] |
| T-cell receptor cross-linking | T-cell hybridoma | N/D | + | [111] |
| Cancer chemotherapeutic agents | ||||
| Camptothecin | 4B1 (human Fas-expressing L929 mouse fibroblasts) | N/D | + | [112] |
| FTC-133 follicular thyroid carcinoma cells | + | + | [97] | |
| Doxorubicin | MCF-7 breast carcinoma cells | N/D | + | [113] |
| Rat primary astrocytes | N/D | + | [114] | |
| FTC-133 follicular thyroid carcinoma cells | + | + | [97] | |
| Daunorubicin | P388 lymphocytic leukaemia cells | + | + | [60] |
| Hen follicular granulosa cells | N/D | + | [115] | |
| Etoposide | MOLT4 leukaemia cells | + | + | [116] |
| Fenretinide (4-HPR) | HL-60 promyelocytic leukaemia | + | + | [117] |
| Endothelial cells | + | + | [118] | |
| Fludarabine | Chronic B-cell leukaemia | + | + | [119] |
| LNCaP prostate cancer cells | + | + | [120] | |
| Inostamycin | Ms-1 small cell lung carcinoma cells | + | + | [121] |
| Oxaliplatin + SK inhibitor | RKO colon carcinoma cells | + | + | [122] |
| Vascular endothelial growth factor inhibitor SU5416 | Mouse lung | N/D | + | [101] |
| IR and non-IR | ||||
| γ-Irradiation | Mouse colonic crypts | N/D | + | [105] |
| Human lymphoblasts | + | + | [123] | |
| LNCaP prostate cancer cells | + | + | [106] | |
| 125I-Labelled 5-iodo-29-deoxyuridine | Bovine aortic endothelial cells | + | + | [102] |
| UV-B | Human keratinocytes | + | + | [100] |
| UV-C | Hen follicular granulosa cells | N/D | + | [115] |